US 11,723,709 B2
System, method and computer-accessible medium for in-vivo tissue ablation and/or damage
Govindarajan Srimathveeravalli, Amherst, MA (US); and Stephen Barnett Solomon, New York, NY (US)
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed on Jul. 13, 2020, as Appl. No. 16/927,261.
Application 16/927,261 is a continuation of application No. 14/910,600, granted, now 10,709,491, issued on Jul. 14, 2020, previously published as PCT/US2014/049880, filed on Aug. 6, 2014.
Claims priority of provisional application 61/862,580, filed on Aug. 6, 2013.
Prior Publication US 2021/0000527 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 18/12 (2006.01); A61B 6/03 (2006.01); A61B 18/00 (2006.01); A61B 90/00 (2016.01); A61B 18/18 (2006.01); A61B 18/14 (2006.01); A61B 34/20 (2016.01); A61B 17/00 (2006.01)
CPC A61B 18/12 (2013.01) [A61B 6/037 (2013.01); A61B 18/1206 (2013.01); A61B 18/1233 (2013.01); A61B 18/1492 (2013.01); A61B 18/1815 (2013.01); A61B 2017/00194 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00648 (2013.01); A61B 2018/00666 (2013.01); A61B 2018/00726 (2013.01); A61B 2018/00761 (2013.01); A61B 2018/00767 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00827 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/143 (2013.01); A61B 2018/1475 (2013.01); A61B 2034/2057 (2016.02); A61B 2090/373 (2016.02); A61B 2090/374 (2016.02); A61B 2090/378 (2016.02); A61B 2090/3762 (2016.02)] 30 Claims
OG exemplary drawing
 
1. A non-transitory computer-accessible medium having stored thereon computer-executable instructions for ablating at least one electrically-sensitive tissue, wherein, when a computer hardware arrangement executes the instructions, the computer hardware arrangement is configured to perform procedures comprising:
establishing particular parameters for electric pulses based on at least one characteristic of the at least one electrically-sensitive tissue;
controlling an application of the electric pulses to all of the at least one electrically-sensitive tissue for a plurality of automatically controlled and separated time periods to ablate less than all of the at least one electrically-sensitive tissue such that a substantial electroporation of a majority of the at least one electrically-sensitive tissue is at least one of prevented or reduced; and
controlling an impedance level of the at least one electrically-sensitive tissue while the electric pulses are applied.